Ongoing Collaboration with Basilea Pharmaceutica International Ltd and their Lisavanbulin Clinical Program in Glioblastoma Will Be Highlighted at ASCO
DURHAM, NC / ACCESSWIRE / June 2, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually June 4th through 8th. The presentations will focus on the ongoing collaborations with Basilea Pharmaceutica International Ltd and their Lisavanbulin Phase 2 clinical program in glioblastoma. Lisavanbulin is a prodrug of the lipophilic small molecule BAL27862, a novel tumor checkpoint controller that promotes tumor cell death by modulating the spindle assembly checkpoint. A key aspect of the current collaboration is the development of biomarkers, including differentially expressed genes, that may predict response to lisavanbulin and could serve as a potential predictive response signature in glioblastoma and other tumor types.
Details of the poster presentations are as follows:
- Title: Expression of end-binding protein 1 (EB1), a potential response-predictive biomarker for lisavanbulin, in glioblastoma and various other solid tumor types.
- Session: Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology
- Date: 4 June 2021
- Abstract Number: 3118
- Title: The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.
- Session: Central Nervous System Tumors
- Date: 4 June 2021
- Abstract Number: TPS2068
GeneCentric’s RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer platform and the associated pipeline of response signatures is being leveraged alongside traditional immunohistochemistry (IHC) to better characterize patients most likely to respond to lisavanbulin.
“We are excited to highlight ongoing clinical collaborations and our novel RNA-based technologies at the ASCO annual meeting,” said Michael Milburn, PhD, GeneCentric President and CEO. ” While most conferences have been virtual this past year, GeneCentric has experienced expansive growth in collaborations as well as enhanced interest in our deep expertise in RNA-based genomic solutions which parse out the complexities of tumor biology.”
GeneCentric Therapeutics, Inc., based in Research Triangle Park, N.C., is an RNA-based genomic solutions provider. The company’s technologies are designed to parse the complexity of tumor and immune biology using its RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer platform to discover and develop signatures of responder populations to oncology therapeutics. GeneCentric is commercializing its technology through strategic collaborations with pharmaceutical, biotechnology, and diagnostics companies in applications throughout pre-clinical testing, clinical drug development, and commercialization lifecycle phases. For more information, please visit www.genecentric.com.
GeneCentric Therapeutics, Inc.
Joel R. Eisner, Ph.D.
Sr. Vice President – Clinical & Corporate Development
SOURCE: GeneCentric Therapeutics, Inc.